GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » EPS without NRI

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) EPS without NRI

: $7.50 (TTM As of Dec. 2023)
View and export this data going back to 1952. Start your Free Trial

Bristol-Myers Squibb Co's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $1.70. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $7.50.

During the past 12 months, Bristol-Myers Squibb Co's average earnings per share (NRI) Growth Rate was -2.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 5.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 14.80% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bristol-Myers Squibb Co's EPS without NRI or its related term are showing as below:

BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.9   Med: 9.95   Max: 36.1
Current: 5.3

During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 36.10% per year. The lowest was -20.90% per year. And the median was 9.95% per year.

BMY's 3-Year EPS without NRI Growth Rate is ranked worse than
58.22% of 833 companies
in the Drug Manufacturers industry
Industry Median: 11.3 vs BMY: 5.30

Bristol-Myers Squibb Co's EPS (Diluted) for the three months ended in Dec. 2023 was $0.87. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.86.

Bristol-Myers Squibb Co's EPS (Basic) for the three months ended in Dec. 2023 was $0.87. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.88.


Bristol-Myers Squibb Co EPS without NRI Historical Data

The historical data trend for Bristol-Myers Squibb Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 6.44 7.51 7.70 7.51

Bristol-Myers Squibb Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 2.05 1.75 2.00 1.70

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co PE Ratio without NRI Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's PE Ratio without NRI falls into.



Bristol-Myers Squibb Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (NYSE:BMY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bristol-Myers Squibb Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Executives
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von officer: SVP, Enterp. Services & CIO BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543